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Summary
Testing for the presence of antibody to hepatitis C virus (anti-HCV) is recommended for initially identifying persons with
hepatitis C virus (HCV) infection (CDC. Recommendations for prevention and control of hepatitis C virus [HCV] infec-
tion and HCV-related chronic disease. MMWR 1998;47[No. RR-19]:1–33). Testing for anti-HCV should include use of an
antibody screening assay, and for screening test-positive results, a more specific supplemental assay. Verifying the presence of anti-
HCV minimizes unnecessary medical visits and psychological harm for persons who test falsely positive by screening assays and
ensures that counseling, medical referral, and evaluation are targeted for patients serologically confirmed as having been infected with
HCV. However, substantial variation in reflex supplemental testing practices exists among laboratories, and an anti-HCV–positive
laboratory report does not uniformly represent a confirmed positive result. These guidelines expand recommendations for anti-
HCV testing to include an option for reflex supplemental testing based on screening-test–positive signal-to-cut–off (s/co) ratios. Use
of s/co ratios minimizes the amount of supplemental testing that needs to be performed while improving the reliability of reported
test results. These guidelines were developed on the basis of available knowledge of CDC staff in consultation with representatives
from the Food and Drug Administration and public health, hospital, and independent laboratories. Adoption of these guidelines
by all public and private laboratories that perform in vitro diagnostic anti-HCV testing will improve the accuracy and utility of
reported anti-HCV test results for counseling and medical evaluation of patients by health-care professionals and for surveillance
by public health departments.
Introduction
Tests to detect antibody to hepatitis C virus (anti-HCV)
were first licensed by the Food and Drug Administration (FDA)
in 1990 (1). Since that time, new versions of these and other
FDA-approved anti-HCV tests have been used widely for clini-
cal diagnosis and screening of asymptomatic persons.
Persons being tested for anti-HCV are entitled to accurate
and correctly interpreted test results. CDC has recommended
that a person be considered to have serologic evidence of HCV
infection only after an anti-HCV screening-test–positive
result has been verified by a more specific serologic test (e.g.,
the recombinant immunoblot assay [RIBA®; Chiron
Corporation, Emeryville, California]) or a nucleic acid test
(NAT) (2). This recommendation is consistent with testing
practices for hepatitis B surface antigen and antibody to human
immunodeficiency virus (HIV), for which laboratories
routinely conduct more specific reflex testing before
reporting a result as positive (1,3). However, for anti-HCV,
the majority of laboratories report a positive result based on a
positive screening test result only, and do not verify these
results with more specific serologic or nucleic acid testing
unless ordered by the requesting physician. Unfortunately, cer-
tain health-care professionals lack an understanding of the
interpretation of anti-HCV screening test results, when more
specific testing should be performed, and which tests should
be considered for this purpose.
In certain clinical settings, false-positive anti-HCV results
are rare because the majority of persons being tested have evi-
dence of liver disease and the sensitivity and specificity of the
screening assays are high. However, among populations with
a low (<10%) prevalence of HCV infection, false-positive
results do occur (4–11). This is of concern when testing is
performed on asymptomatic persons for whom no clinical
information is available, when persons are being tested for
HCV infection for the first time, and when testing is
being used to determine the need for postexposure follow-up.
Without knowledge of the origin of the test sample or clinical
* These guidelines are not intended to be used for blood, plasma, organ, tissue,
or other donor screening or notification as provided for under FDA guidance
or applicable regulations. They also are not intended to change the
manufacturer’s labeling for performing a specific test.
2 MMWR February 7, 2003
information concerning the person being tested, the accuracy
of a screening-test–positive result for any given specimen can-
not be determined.
Multiple reasons exist regarding why laboratories do not
perform reflex supplemental testing for anti-HCV, including
lack of an established laboratory standard for such testing,
lack of understanding regarding the performance and inter-
pretation of the screening and supplemental HCV tests, and
the high cost of the supplemental HCV tests. To facilitate prac-
tice of reflex supplemental testing, the recommended anti-
HCV testing algorithm has been expanded to include an option
that uses the signal-to-cut–off (s/co) ratios of screening-
test–positive results to minimize the number of specimens that
require supplemental testing and provide a result that has
a high probability of reflecting the person’s true antibody
status.
Background
Available Anti-HCV Screening Assays
FDA-licensed or approved anti-HCV screening test kits
being used in the United States comprise three immunoas-
says; two enzyme immunoassays (EIA) (Abbott HCV EIA 2.0,
Abbott Laboratories, Abbott Park, Illinois, and ORTHO®
HCV Version 3.0 ELISA, Ortho-Clinical Diagnostics, Raritan,
New Jersey) and one enhanced chemiluminescence
immunoassay (CIA) (VITROS® Anti-HCV assay, Ortho-
Clinical Diagnostics, Raritan, New Jersey). All of these
immunoassays use HCV-encoded recombinant antigens.
Available Supplemental Tests
Supplemental tests include a serologic anti-HCV assay and
NATs for HCV RNA. In the United States, the only FDA-
licensed supplemental anti-HCV test is the strip immunoblot
assay (Chiron RIBA® HCV 3.0 SIA, Chiron Corp.,
Emeryville, California). RIBA 3.0 uses both HCV-encoded
recombinant antigens and synthetic peptides. Because it is a
serologic assay, it can be performed on the same serum or
plasma sample collected for the screening anti-HCV assay.
FDA-approved diagnostic NATs for qualitative detection
of HCV RNA using reverse transcriptase polymerase chain
reaction (RT-PCR) amplification include AMPLICOR®
Hepatitis C Virus (HCV) Test, version 2.0 and COBAS
AMPLICOR® Hepatitis C Virus Test, version 2.0 (Roche
Molecular Systems, Branchburg, New Jersey), which have a
lower limit of detection of approximately 50 IU/mL (12).
Detection of HCV RNA by these tests requires that the serum
or plasma sample be collected and handled in a manner suit-
able for NAT and that testing be performed in a laboratory
with facilities established for this purpose (see Recommenda-
tions). Other NATs for HCV RNA, both qualitative and quan-
titative, are available on a research-use basis from multiple
manufacturers of diagnostic reagents, and certain laboratories
perform NATs by using in-house laboratory methods and
reagents (12,13).
Interpreting Anti-HCV Test Results
Screening Immunoassay Test Results
Anti-HCV testing includes initial screening with an immu-
noassay. Criteria for interpretation of a reactive† anti-HCV
immunoassay result are based on data from clinical studies
performed under the auspices of each manufacturer. For EIAs
(e.g., HCV EIA 2.0 and HCV Version 3.0 ELISA), speci-
mens with a reactive result are retested in duplicate. If the
result of either duplicate test is reactive, the specimen is
defined as repeatedly reactive and is interpreted as screening-
test–positive. For CIAs, (e.g., VITROS Anti-HCV assay),
specimens with a single reactive result are considered screening-
test–positive and do not require retesting.
The specificity of the HCV EIA 2.0 and HCV Version 3.0
ELISA is >99%. However, among a population with a low
prevalence of infection, even a specificity of 99% does not
provide the desired predictive value for a positive test. Among
immunocompetent populations with anti-HCV prevalences
<10% (e.g., volunteer blood donors, active duty and retired
military personnel, persons in the general population, health-
care workers, or clients attending sexually transmitted disease
[STD] clinics), the proportion of false-positive results with
HCV EIA 2.0 or HCV Version 3.0 ELISA averages approxi-
mately 35% (range: 15%–60%) (4–11; CDC, unpublished
data, 2002). Among immunocompromised populations (e.g.,
hemodialysis patients), the proportion of false-positive results
averages approximately 15% (14; CDC, unpublished data,
2002). For this reason, not relying exclusively on anti-HCV
screening-test–positive results to determine whether a person
has been infected with HCV is critical. Rather, screening-test–
positive results should be verified with an independent supple-
mental test with high specificity.
† The terms reactive or nonreactive are used to describe serum or plasma
specimen test results from anti-HCV screening immunoassays before final
interpretation. The terms positive and negative are used to describe the final
interpretation of screening immunoassay test results (e.g., screening-test–
positive indicates that the specimen tested is repeatedly reactive by EIA or
reactive by CIA, or screening-test–negative indicates that the specimen tested
is nonreactive or not repeatedly reactive). The terms positive, indeterminate,
and negative are used to describe the interpretation of RIBA results based
on reactivity with a specific pattern of bands.
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anti-HCV test results are negative (screening-test–negative or
RIBA-negative) are considered uninfected (Box). However,
false-negative anti-HCV test results can occur during the first
weeks after infection (i.e., before antibody is detectable or
during seroconversion), although HCV RNA can be detected
as early as 1–2 weeks after exposure to the virus (16,17). Rarely,
antibody seroconversion might be delayed for months after
exposure (18,19). In certain persons whose HCV infection
has resolved, anti-HCV declines below detectable levels (20).
Occasionally, persons with chronic HCV infection, includ-
ing those who are immunocompromised, are persistently anti-
HCV–negative, and detection of HCV RNA might be the
only evidence of infection (14,21).
An indeterminate RIBA result indicates that the anti-HCV
result cannot be determined (Box). Indeterminate anti-HCV
supplemental test results have been observed in recently
infected persons who are in the process of seroconversion, and
occasionally in persons chronically infected with HCV (22).
Indeterminate results also might indicate a false-positive screen-
ing test result, which is the most common interpretation for
Supplemental Serologic Test Results
The strip immunoblot assay (RIBA), a supplemental anti-
HCV test with high specificity, is performed on screening-
test–positive samples and provides results that are interpreted
as positive, negative, or indeterminate. A positive RIBA result
is interpreted as anti-HCV–positive (Box). Although the pres-
ence of anti-HCV does not distinguish between current or
past infection, a confirmed anti-HCV–positive result indi-
cates the need for counseling and medical evaluation for HCV
infection, including additional testing for the presence of
virus (NAT for HCV RNA) and liver disease (e.g., alanine
aminotransferase [ALT]) (2,15). Anti-HCV testing usually
does not need to be repeated after the anti-HCV–positive re-
sult has been confirmed.
A negative RIBA result is interpreted as anti-HCV–negative
and indicates a false-positive screening test result. In this situ-
ation, the additional testing with RIBA minimizes unneces-
sary medical visits and psychological harm from reporting a
false-positive screening test result. Typically, persons whose
• An anti-HCV–negative person is considered  uninfected.
• No further evaluation or follow-up for HCV is
required, unless recent infection is suspected or other
evidence exists to indicate HCV infection  (e.g.,
abnormal liver enzyme levels in an immuno-
compromised person or a person with no other etiol-
ogy for their liver disease).
Anti-HCV–Indeterminate
An indeterminate anti-HCV result is defined as anti-
HCV screening-test–positive, RIBA-indeterminate.
• An indeterminate anti-HCV result indicates that the
HCV antibody status cannot be determined.
— Can indicate a false-positive anti-HCV screening
test result, the most likely interpretation among
those at low risk for HCV infection; such persons
are HCV RNA-negative.
— Can occur as a transient finding in a recently in-
fected person who is in the process of
seroconversion; such persons usually are HCV
RNA-positive.
— Can be a persistent finding among persons chroni-
cally infected with HCV; such persons usually are
HCV RNA-positive.
• If NAT is not performed, another sample should be
collected for repeat anti-HCV testing (>1 month later).
BOX. Interpreting antibody to hepatitis C virus (anti-HCV) test results
Anti-HCV–Positive
An anti-HCV–positive result is defined as 1) anti-HCV
screening-test-positive* and recombinant immunoblot
assay (RIBA®)- or nucleic acid test (NAT)-positive; or
2) anti-HCV screening-test–positive, NAT-negative,
RIBA-positive.
• An anti-HCV–positive result indicates past or cur-
rent HCV infection.
— An HCV RNA-positive result indicates current
(active) infection, but the significance of a single
HCV RNA-negative result is unknown; it does not
differentiate intermittent viremia from resolved in-
fection.
• All anti-HCV–positive persons should receive coun-
seling and undergo medical evaluation, including ad-
ditional testing for the presence of virus and liver
disease.
— Anti-HCV testing usually does not need to be re-
peated after a positive anti-HCV result has been
confirmed.
Anti-HCV–Negative
An anti-HCV–negative result is defined as 1) anti-HCV
screening-test–negative*; or 2) anti-HCV screening-test–
positive, RIBA-negative; or 3) anti-HCV screening-test–
positive, NAT-negative, RIBA-negative.
* Interpretation of screening immunoassay test results based on criteria provided by the manufacturer.
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these results among those at low risk for HCV infection
(23,24). Another sample should be collected for repeat anti-
HCV testing (>1 month later) or for HCV RNA testing.
Supplemental NAT Results
NATs that detect HCV RNA also can be used as supple-
mental tests for anti-HCV. They are used commonly in clini-
cal practice for diagnosis of acute and chronic HCV infection
and for evaluating and managing patients with chronic
hepatitis C.
If the NAT result is positive in persons with a positive screen-
ing test result, NAT has the advantage of detecting the pres-
ence of active HCV infection as well as verifying the presence
of anti-HCV (Box). If the NAT result is negative in persons
with a positive screening test result, the HCV antibody or in-
fection status cannot be determined. Among persons with these
results, additional testing with RIBA is necessary to verify the
anti-HCV result and determine the need for counseling and
medical evaluation (Box); if the anti-HCV screening test
results are judged falsely positive (i.e., RIBA-negative), no fur-
ther evaluation of the person is needed; whereas if the anti-
HCV screening test results are verified as positive by RIBA,
the person should undergo medical evaluation, including
serial determinations of HCV RNA and ALT activity.
Certain situations exist in which the HCV RNA result can
be negative in persons with active HCV infection. As the titer
of anti-HCV increases during acute infection, the titer of HCV
RNA declines (17). Thus, HCV RNA is not detectable in cer-
tain persons during the acute phase of their hepatitis C, but
this finding can be transient and chronic infection can de-
velop (25). In addition, intermittent HCV RNA positivity has
been observed among persons with chronic HCV
infection (21,26,27). Therefore, in the absence of additional
clinical information, the significance of a single negative HCV
RNA result is unknown, and the need for further medical evalu-
ation is determined by verifying anti-HCV status.
A negative HCV RNA result also can indicate resolved
infection. Among anti-HCV–positive persons who acquired
their HCV infection as older adults (aged >45 years), 15%–
25% apparently resolve their infection; this proportion is higher
(40%–45%) among anti-HCV–positive persons who acquired
their infection as children or younger adults (20). To deter-
mine if HCV infection has resolved, a negative HCV RNA
result should be demonstrated on multiple occasions; how-
ever, such follow-up testing is indicated only in persons with
serologically confirmed anti-HCV positive results.
Anti-HCV Testing Practices
Multiple commercial, hospital-based, and public health labo-
ratories that perform anti-HCV testing routinely report screen-
ing test results only. More specific testing (i.e., RIBA or NAT)
is performed only when ordered by a physician. Moreover, in
certain laboratories, more specific tests are not available.
During 2002, two surveys regarding anti-HCV testing prac-
tices were performed, one by the Association of Public Health
Laboratories (Barbara Werner, Ph.D., Association of Public
Health Laboratories, personal communication, September
2002) and one by a Veterans Affairs (VA) Medical Center
(D. Robert Dufour, M.D., VA Medical Center, Washington,
D.C., personal communication, October 2002). Forty-three
(80%) of 54 U.S. state and territorial public health laborato-
ries and 67 (39%) of 172 VA medical center laboratories
responded (Table 1).
Of the respondents, the public health laboratories were less
likely to offer screening or supplemental tests for HCV than
were the hospital-based VA laboratories. However, the public
health laboratories that did offer both types of testing were
more likely to perform reflex supplemental testing than were
the hospital-based laboratories, 75% of which performed
supplemental testing only by physician request. Regarding
the type of supplemental testing performed, the majority of
hospital-based laboratories performed only NATs, whereas the
public health laboratories most commonly performed either
RIBA alone or NAT followed by RIBA if the NAT result was
negative.
Although substantial differences existed in testing practices
between and among these two types of laboratories, the
majority of public and private sector laboratories depend on
the requesting physician to be knowledgeable concerning the
TABLE 1. Antibody to hepatitis C virus testing practices of
state and territorial public health laboratories and Veterans
Affairs Medical Center (VAMC) laboratories, 2002
Public health VAMC
Testing practices laboratories laboratories
Tests offered n = 43 n = 67
Screening test 65% 100%
Recombinant immunoblot assay (RIBA®) 38% 21%
Qualitative nucleic acid test (NAT) 29% 75%
Quantitative NAT 13% 98%
Supplemental testing performed n = 29 n = 67
All screening-test–positive results 35% 22%
Low-positive* screening-test results 10% 3%
Only by physician request 17% 75%
None offered 38% 0%
Type of supplemental test performed† n = 13 n = 16
RIBA only 31% 31%
NAT only 15% 63%
NAT followed by RIBA, if NAT-negative 39% 6%
RIBA followed by NAT, if RIBA-positive 15% 0%
* Signal-to-cut–off ratio below a specified value.† Includes only laboratories that routinely performed supplemental testing
on all specimens with screening-test–positive results or with low-positive
results.
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appropriate tests to order and the correct interpretation of
their results. However, a general lack of understanding exists
among health-care professionals regarding the interpretation
of screening test results, when more specific testing should be
performed, and which tests should be considered for this pur-
pose.
Using Screening-Test–Positive S/Co
Ratios To Determine Need for Reflex
Supplemental Testing
Analysis of early versions of anti-HCV EIA results from
volunteer blood donors indicated that average repeatedly
reactive s/co ratios could be used to predict supplemental test-
positive results (28). Similar data from volunteer blood
donors were generated by using HCV Version 3.0 ELISA, for
which the average s/co ratios of 24,700 samples repeatedly
reactive for anti-HCV were compared with their RIBA 3.0
results (Susan Stramer, Ph.D., American Red Cross, personal
communication, March 1999). Overall, 64.0% were RIBA-
positive. The proportion that tested RIBA-positive was 5.8%
for samples with an average s/co ratio 1.0–2.9; 37.1% for those
with average s/co ratio 3.0–3.4; 67% for those with average
s/co ratio 3.5–3.7; 88.1% for those with average s/co ratio
3.8–3.9; and 94.1% for those with average s/co ratio >4.0.
Additional data from other populations were generated by
CDC to determine if a specific s/co ratio could be identified
that would predict a true antibody-positive result >95% of
the time, regardless of the anti-HCV prevalence or character-
istics of the population being tested. The anti-HCV screening
tests evaluated were the two FDA-licensed EIAs, HCV EIA
2.0 and HCV Version 3.0 ELISA, and the one FDA-approved
CIA, VITROS Anti-HCV assay.
EIAs
All specimens with EIA screening-test–positive results were
tested by RIBA 3.0, and a sample of screening-test–positive
specimens were tested for HCV RNA by >2 of the following
NAT methods: transcription-mediated amplification (TMA)
(Procleix™, Chiron Corporation, Emeryville, California);
AMPLICOR; and nested RT-PCR (13). Test results were used
from serum samples that had been collected as part of CDC-
sponsored anti-HCV seroprevalence studies that were con-
ducted among different groups of asymptomatic persons
(Robert Gunn, M.D., San Diego County Department of
Health and Human Services Agency; Steven Harris, M.D.,
Travis County, Texas Department of Health; Lu-Yu Hwang,
M.D., University of Texas — Houston School of Public
Health; Leslie Tobler, Ph.D., Blood Centers of the Pacific,
San Francisco; Gayle Shimokura, University of North Caro-
lina at Chapel Hill School of Public Health; Isaac Weisfuse,
M.D., New York City Department of Health and Mental
Hygiene, personal communications, 2001–2002; CDC,
unpublished data, 2002). Anti-HCV prevalences ranged from
0.8% to 25% (Table 2).
The proportion of screening-test–positive results that were
serologically confirmed as anti-HCV–positive (i.e., RIBA-
positive) increased as the anti-HCV prevalence in the popula-
tion increased (Table 2). Conversely, the proportion of
screening-test–positive results that were falsely antibody-
positive (RIBA-negative) or RIBA-indeterminate was inversely
related to prevalence (Table 2).
For each study group, the proportion of screening-test–
positive results that were RIBA-positive increased as the screen-
ing-test–positive average s/co ratios increased (Figure 1). On
the basis of these data, screening-test–positive average s/co
TABLE 2. Antibody to hepatitis C virus (anti-HCV) screening-test–positive average signal-to-cut–off (s/co) ratios by recombinant
immunoblot assay (RIBA®) 3.0 and nucleic acid test (NAT) results in groups with different anti-HCV prevalences
No. (%) HCV RNA-
Anti-HCV Total Average screening- RIBA results (%) positive
prevalence                   Study group tested* s/co ratio test–positive Negative Ind† Positive  (%)
2% (average) Multiple groups§ with prevalences 24,012 Total 689 (100.0) 26.9 7.3 65.9 41.6¶
ranging from 0.8% to 4.4% <3.8 231 (33.5) 78.8 16.9 4.3 3.7
>3.8 458 (66.5) 0.7 2.4 96.9 80.2
9.5% Hemodialysis patients 2,936 Total 351 (100.0) 9.7 7.3 83.0 80.3
<3.8 45 (12.8) 64.4 33.3 2.2 4.4
>3.8 306 (87.2) 1.6 3.4 95.0 91.5
24.9% STD clinic clients selected based 498 Total 124 (100.0) 1.6 4.0 94.4 NA††
on risk** <3.8 3  (2.4) 66.7 33.3 0 NA
>3.8 121  (97.6) 0 3.3 96.7 NA
* HCV EIA 2.0 or HCV Version 3.0 ELISA.
† Indeterminate.
§ College students, general population, health-care workers, and sexually transmitted disease (STD) clinic clients not selected by risk factor.
¶ In the low (2%) prevalence group, only a sample of 214 were tested for HCV RNA.
** History of injection-drug use, blood transfusion before 1992, or incarceration.
†† Not available.
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ratios >3.8 were highly predictive of RIBA positivity (>95%),
with limited variability (95%–97%) between groups with dif-
ferent prevalences (Table 2). Screening-test–positive average
s/co ratios >3.8 also were highly predictive of HCV RNA posi-
tivity, although the proportions that were HCV RNA-posi-
tive were slightly lower than those for RIBA (Table 2).
These results indicate that for licensed EIAs, reporting anti-
HCV screening-test–positive results as anti-HCV positive for
samples with average s/co ratios >3.8 would be highly predic-
tive of the true anti-HCV status. Reflex supplemental testing
before reporting the anti-HCV results could be limited to
screening-test–positive samples with average s/co ratios <3.8.
The feasibility of this approach is supported further by the
limited proportion (2.4%) of samples from persons at high
risk that have s/co ratios below this cut-off value. When test-
ing for anti-HCV is performed on persons at increased risk
for infection as recommended (2), a limited number of samples
will require additional testing.
CIA
The relation between s/co ratios and RIBA 3.0 results also
was evaluated for specimens that were screening-test–positive
by CIA (i.e., reactive by VITROS Anti-HCV) from four
groups. These included a group of 162 volunteer blood do-
nors with substantially low anti-HCV prevalence (Leslie Tobler,
Ph.D., Blood Centers of the Pacific, San Francisco, personal
communication, September 2002), a group of 163 persons
with low anti-HCV prevalence (college students, persons in
the general population, and health-care workers as described
previously), a group of 219 hemodialysis patients with inter-
mediate anti-HCV prevalence (as described previously), and
a group of 689 hospital-based patients with high anti-HCV
prevalence (signs or symptoms of liver disease or risk factors
for HCV infection) (D. Robert Dufour, M.D., VA Medical
Center, Washington, D.C., and Michael De Lucia, Ortho-
Clinical Diagnostics, personal communications, September
2002).
Overall, the proportion of CIA screening-test–positive
samples that tested RIBA-positive was 77.8% among the blood
donors, 74.2% among the low prevalence group, 86.3% among
the hemodialysis patients, and 94.5% among the high preva-
lence group. The direct relation between increasing s/co ratios
and RIBA positivity that was observed among samples tested
with the two EIAs evaluated by CDC also was observed among
the samples tested with the CIA (Figure 2). However, the range
of screening-test–positive s/co ratios obtained with VITROS
Anti-HCV was greater than that obtained with HCV EIA 2.0
or HCV Version 3.0 ELISA; thus, s/co ratios that were highly
predictive of RIBA positivity also were higher. Using VITROS
Anti-HCV, an s/co ratio of >8 predicted RIBA positivity in
95%–98% of the screening-test–positive samples (Figure 2).
The proportion of CIA samples with low s/co ratios was in-
versely related to anti-HCV prevalence (i.e., 4.9% in the high
prevalence group, 8.7% in the intermediate prevalence group,
and 21.5% in the low prevalence group). These results indi-
cate that for the FDA-approved CIA, reflex supplemental test-
ing of screening-test–positive samples also could be limited to
those with a low (<8) s/co ratio; and among persons at in-
creased risk for infection, <5% will have s/co ratios below the
cut-off value.
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FIGURE 1. Proportion of antibody to hepatitis C virus enzyme immunoassay* screening-
test–positive results that tested recombinant immunoblot assay (RIBA®) 3.0-positive
by average signal-to-cut–off (s/co) ratios and group tested
* HCV EIA 2.0 or HCV Version 3.0 ELISA.†Sexually transmitted diseases.
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Estimated Costs of Implementing
Reflex Supplemental Testing Based
on Screening-Test–Positive S/Co Ratios
To assist laboratories in assessing the potential financial
impact of implementing reflex supplemental testing for screening-
test–positive samples with low s/co ratios, the incremental costs
associated with such testing were estimated for three hypo-
thetical populations of 10,000 persons each, representing anti-
HCV prevalences of 2%, 10%, and 25%, respectively (similar
to those of the groups evaluated previously). For each popula-
tion, the costs of performing the screening test (by
using EIAs as the example) and each of two different supple-
mental testing schemes (schemes 1 and 2) were compared with
the cost of performing only the screening test (base scheme).
All schemes included performing a screening EIA on each
sample and repeating initially reactive specimens in duplicate.
Scheme 1 also included RIBA testing on all screening-test–
positive samples with average s/co ratios <3.8, and scheme 2
included NAT testing on all screening-test–positive samples
with average s/co ratios <3.8, followed by RIBA on those that
were NAT-negative.
The increased costs for schemes 1 and 2 were calculated per
sample tested compared with the base scheme. For RIBA and
NAT, minimum and maximum costs were estimated; mini-
mum costs were defined as costs for reagents only, and maxi-
mum costs were defined as costs incurred for tests performed
by a referral laboratory. The following assumptions were made:
• The percentage of initially reactive samples that were
repeatedly reactive (screening-test–positive) was assumed
to be 90% in the groups with anti-HCV prevalences of
2% and 10%, and 95% in the group with anti-HCV
prevalence of 25%.
• The proportion of screening-test–positive samples with
average s/co ratios <3.8 and the proportion of such samples
that tested RIBA-positive for each population was derived
(Table 2).
• The proportion of screening-test–positive samples with
average s/co ratios <3.8 that were NAT-positive was
derived (Table 2) for the populations with anti-HCV
prevalences of 2% and 10%. For the population with a
prevalence of 25%, this proportion was assumed to be
zero (on the basis of data from high-prevalence hospital-
based patients) (D. Robert Dufour, M.D., VA Medical
Center, Washington, D.C., personal communication,
September 2002).
Costs were estimated as follows and do not include person-
nel time or additional equipment:
• $5/sample for initial screening test;
• $15/sample for those testing initially reactive and repeated
in duplicate;
• $65–$158/sample tested with RIBA; and
• $50–$295/sample tested with a NAT.
Compared with performing only the screening test, perform-
ing reflex RIBA testing on all screening-test–positive samples
with average s/co ratios <3.8 (scheme 1) increases the cost of
testing per sample for immunocompetent populations from a
minimum of 5%–12% ($0.41–$0.66) to a maximum of 13%–
30% ($1.00–$1.60), depending on the anti-HCV prevalence
FIGURE 2. Proportion of antibody to hepatitis C virus (anti-HCV) enhanced
chemiluminescence immunoassay* screening-test–positive results that tested
recombinant immunoblot assay (RIBA®) 3.0-positive by signal-to-cut–off (s/co) ratios
and group tested
* VITROS® Anti-HCV assay.† College students, general population, and health-care workers.§ Hospital-based patients.
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of the population being tested (Figure 3). For hemodialysis
patients, the cost increases from a minimum of 16% ($1.00)
to a maximum of 38% ($2.44). Performing reflex NATs on
all screening-test–positive samples with average s/co ratios <3.8,
followed by RIBA on those that are NAT-negative (scheme
2), increases the cost of testing per sample for immunocom-
petent populations from a minimum of 9%–21% ($0.73–
$1.14) to a maximum of 37%–85% ($2.88–$4.54), compared
with performing only the screening test. For hemodialysis
patients, the cost increases from a minimum of 27% ($1.73)
to a maximum of 109% ($6.88). The higher incremental costs
of scheme 2 compared with scheme 1 are because virtually all
the screening-test–positive samples with s/co ratios <3.8 test
HCV RNA-negative and require follow-up testing with RIBA
to verify anti-HCV status.
Recommendations
Rationale
Testing for HCV infection by using anti-HCV is performed
for 1) clinical diagnosis of patients with signs or symptoms of
liver disease; 2) management of occupational and perinatal
exposures; and 3) screening asymptomatic persons to identify
HCV-infected persons who should receive counseling and
medical evaluation. Anti-HCV test results also are used for
public health surveillance to monitor incidence and preva-
lence and to target and evaluate HCV prevention efforts.
Anti-HCV testing is performed in multiple settings, includ-
ing hospitals and other health-care facilities, physicians’
offices, health department clinics, HIV or other freestanding
counseling and testing sites, employment sites, and health fairs.
The interpretation of anti-HCV screening-test–positive results
in these settings can be problematic. Clinical information
related to the persons tested often is lacking, and even persons
with risk factors for HCV infection might be at sufficiently
low enough risk for infection that their screening test results
could be falsely positive (e.g., health-care professionals are at
occupational risk for HCV infection, but their overall preva-
lence of infection is low) (29). Without knowledge of the ori-
gin of the test sample or clinical information related to the
person being tested, the accuracy of a screening-test–positive
result for any given specimen cannot be determined.
However, despite previous recommendations for reflex
supplemental testing of all anti-HCV screening-test–positive
results (2), the majority of laboratories report positive anti-
HCV results based only on a positive screening assay. To
facilitate and improve the practice of reflex supplemental test-
ing, the recommended anti-HCV testing algorithm has been
expanded to include an option for more specific testing based
FIGURE 3. Estimated increased cost per sample for reflex supplemental testing of
antibody to hepatitis C virus (anti-HCV) screening-test–positive results with low* average
signal-to-cut–off ratios compared with performing only the screening test among
populations with different anti-HCV prevalences
* <3.8 by HCV EIA 2.0 or HCV Version 3.0 ELISA.† Minimum costs based on reagents only; maximum costs based on testing performed by referral laboratory.§ Includes only hemodialysis patients.
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on the s/co ratios of screening-test–positive results that can be
implemented without substantial increases in testing costs.
Implementation of these recommendations will provide
more reliable results for physicians and their patients, so that
further counseling and clinical evaluation are limited to those
confirmed to have been infected with HCV. This is critical
for persons being tested for HCV infection for the first time,
for persons being tested in nonclinical settings, and for those
being tested to determine the need for postexposure follow-
up. Implementation of these recommendations also will im-
prove public health surveillance systems for monitoring the
effect of HCV prevention and control activities.
Laboratory Algorithm for Anti-HCV
Testing and Result Reporting
All laboratories that provide anti-HCV testing should per-
form initial screening with an FDA-licensed or approved anti-
HCV test according to the manufacturer’s labeling.
• Screening-test–negative (i.e., nonreactive) samples require
no further testing and can be reported as anti-HCV–
negative (Figure 4).
• Screening-test–positive samples require reflex serologic or
nucleic acid supplemental testing according to the testing
algorithm (Figure 4). Laboratorians can choose to per-
form reflex supplemental testing 1) based on screening-
test–positive s/co ratios, or 2) on all specimens with
screening-test–positive results.
FIGURE 4. Laboratory algorithm for antibody to hepatitis C virus (anti-HCV) testing and result reporting
*  Interpretation of screening immunoassay test results based on criteria provided by the manufacturer.†Signal-to-cut–off.§Screening-test–positive results are classified as having high s/co ratios if their ratios are at or above a predetermined value that predicts a supplemental-
test–positive result >95% of the time among all populations tested; screening-test–positive results are classified as having low s/co ratios if their ratios are
below this value.¶ Recombinant immunoblot assay.
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— For screening-test–positive samples that require reflex
supplemental testing (according to the testing option
chosen), the anti-HCV result should not be reported
until the results from the additional tests are available.
Reflex Supplemental Testing Based
on Screening-Test–Positive S/Co Ratios
• Laboratories should use only screening tests that have been
evaluated for this purpose§ and for which high s/co ratios
have been demonstrated to predict a supplemental-test–
positive >95% of the time among all populations tested.
• Screening-test–positive samples with high s/co ratios can
be reported as anti-HCV–positive without supplemental
testing (Figure 4).
• A comment should accompany the report indicating that
supplemental serologic testing was not performed, and it
should include a statement that samples with high s/co
ratios usually (>95%) confirm positive, but <5 of every
100 samples with these results might be false-positives.
The ordering physician also should be informed that more
specific testing can be requested, if indicated.
• Screening-test–positive samples with low s/co ratios should
have reflex supplemental testing performed, preferably
RIBA (Figure 4).
Reflex Supplemental Testing on All Specimens
with Screening-Test–Positive Results
• RIBA only; or
• NAT, followed by RIBA for specimens with NAT-
negative results (Figure 4).
Considerations When Choosing a Reflex
Supplemental Testing Option
Serologic Supplemental Testing.
• RIBA can be performed on the same sample collected for
the screening test.
• RIBA is the most cost-effective supplemental test for veri-
fying anti-HCV status for screening-test–positive samples
with low s/co ratios.
• The RIBA result is used to report the anti-HCV result.
Nucleic Acid Supplemental Testing.
• NATs can be performed in laboratories that have facilities
specifically designed for that purpose.
• Serum or plasma samples must be collected, processed,
and stored in a manner suitable for NATs to minimize
false-negative results (30).
— Blood should be collected in sterile collection tubes
with no additives or in sterile tubes by using
ethylenediaminetetraacetic acid (EDTA).
— Serum or EDTA plasma must be separated from cel-
lular components within 2–6 hours after collection.
— Storage of serum or EDTA plasma at 2ºC–5ºC is
limited to 72 hours; for longer storage, freezing at
–20ºC or –70ºC is recommended. If shipping is
required, frozen samples should be protected from
thawing.
— Samples collected for serologic testing can be used only
if the previous conditions are met.
• Because of assay variability, rigorous quality assurance and
control should be standards of practice in clinical labora-
tories performing this assay; proficiency testing is recom-
mended, including monitoring for false-positive results.
— Technician proficiency can vary and increases in
direct relation to experience.
— Intra-assay contamination can occur, including aero-
solization, splashing, and carry-over.
• If the HCV RNA result is positive, the presence of active
HCV infection can be reported as well as a positive anti-
HCV result.
• An HCV RNA-negative result requires that RIBA be per-
formed and the RIBA result used to report the anti-HCV
result.
Other Reflex Supplemental Testing Options
Certain laboratories might choose to modify the recom-
mended supplemental testing options to provide additional
information before reporting results. One such modification
might include reflex NAT of screening-test–positive results
with high s/co ratios, which might be of interest to hospital-
based laboratories that usually test specimens from patients
being evaluated for liver disease. If the NAT result is positive,
the presence of active HCV infection can be reported as well
as a positive anti-HCV result. However, if the NAT result is
negative, reflex RIBA testing still is required before reporting
the results to verify the anti-HCV status. Certain specimens
will test RIBA-positive, indicating that the person should
receive further evaluation, including repeat testing for HCV
RNA (see Interpretation of Anti-HCV Test Results).
Implementation
To implement these recommendations for anti-HCV test-
ing and result reporting, laboratories should review their present
§ Data are available from three screening assays. For the two EIAs (HCV EIA
2.0 or HCV Version 3.0 ELISA), high s/co ratios are defined as screening-
test–positive results with average s/co ratios >3.8, and low s/co ratios as
screening-test–positive results with average s/co ratios <3.8. For CIA (VITROS
Anti-HCV), high s/co ratios are defined as screening-test–positive results with
s/co ratios >8, and low s/co ratios as screening-test–positive results with s/co
ratios <8.
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testing and reporting methods and determine how those should
be modified. This process should include
• determining which reflex supplemental testing option will
be implemented;
• revising standard operating procedures to include the
reflex testing option selected (Figure 4), the procedure for
reporting results, and the interpretation of those results
(Table 3);
• educating the laboratory staff, physicians, and other end-
users; and
• modifying the laboratory requisition form, if necessary.
For purposes of reimbursement, the circumstances under
which reflex supplemental testing will be performed might
need to be included on the form to serve as documenta-
tion that the additional tests were ordered.
Laboratories that select a reflex supplemental testing option
based on screening-test–positive s/co ratios need to ensure that
their analyzers generate optical density (OD) values in a range
sufficient to calculate s/co ratios at or above the value defined
as a high s/co ratio for the screening test being used. The s/co
ratio is calculated by dividing the OD value of the sample
being tested by the OD value of the assay cut-off for that run.
Depending on the type of equipment in the laboratory, the
calculation of s/co ratios might be automatically performed
by the analyzer or require that the technician manually per-
form the calculation.
For screening tests that require only one reactive result to
indicate a screening-test–positive result (e.g., VITROS Anti-
HCV), the s/co ratio of the reactive result is used to deter-
mine the next step in the algorithm (i.e., reporting the result
or reflex supplemental testing). For screening tests that require
repeating initially reactive results in duplicate (e.g, HCV EIA
2.0 and HCV Version 3.0 ELISA), the s/co ratio of each of
the duplicate results is calculated. The average of the s/co
ratios of the reactive results is used to determine the next step
in the algorithm. If all three results are reactive for the sample,
the average s/co ratio can be determined either by averaging
the ratios of all three or by averaging only the ratios of the two
duplicate reactive results. If only one of the duplicate results is
reactive, the average s/co ratio is determined by averaging the
TABLE 3. Recommendations for reporting results of testing for antibody to hepatitis C virus (anti-HCV) by type of reflex
supplemental testing performed
Anti-HCV screening test results
Screening-test–negative*
Screening-test–positive*
with high signal-to-cut–off
(s/co) ratio
Screening-test–positive
Screening-test–positive
Screening-test–positive
Screening-test–positive
Screening-test–positive
Screening-test–positive
Screening-test–positive
Supplemental test results
Not applicable
Not done
Recombinant immunoblot
assay (RIBA®)-positive
RIBA-negative
RIBA-indeterminate
Nucleic acid test
(NAT)-positive
NAT-negative
RIBA-positive
NAT-negative
RIBA-negative
NAT-negative
RIBA-indeterminate
Interpretation
Anti-HCV–negative
Anti-HCV–positive
Anti-HCV–positive
Anti-HCV–negative
Anti-HCV–indeterminate
Anti-HCV–positive,
HCV RNA-positive
Anti-HCV–positive,
HCV RNA-negative
Anti-HCV–negative,
HCV RNA-negative
Anti-HCV-indeterminate
HCV RNA-negative
Comments
Not infected with HCV, unless recent infection is
suspected or other evidence exists to indicate HCV
infection
Probably indicates past or present HCV infection;
supplemental serologic testing not performed.
Samples with high s/co ratios usually (>95%)
confirm positive, but <5 of every 100 might
represent false-positives; more specific testing can
be requested, if indicated
Indicates past or present HCV infection
Not infected with HCV, unless recent infection is
suspected or other evidence exists to indicate HCV
infection
HCV antibody and infection status cannot be
determined; another sample should be collected for
repeat anti-HCV testing (>1 month) or for HCV RNA
testing
Indicates active HCV infection
The presence of anti-HCV indicates past or present
HCV infection; a single negative HCV RNA result
does not rule out active infection
Not infected with HCV
Screening test anti-HCV result probably a false-
positive, which indicates no HCV infection
* Screening immunoassay test results interpreted as negative or positive on the basis of criteria provided by the manufacturer.
12 MMWR February 7, 2003
ratios from the initial reactive result and the one duplicate
reactive result.
For those screening-test–positive samples that undergo
reflex supplemental testing (according to the testing option
chosen), the screening test anti-HCV results should not be
reported before the results from the additional testing are avail-
able. If necessary, an interim report can be issued indicating
that the result is pending. This procedure should be followed
even if the laboratory does not perform the supplemental test-
ing in-house, but sends the sample to another reference labo-
ratory for such testing. After the results are received from the
reference laboratory, the final results can be reported on the
basis of the testing performed by both laboratories.
The reported results should be accompanied by interpretive
comments as determined by each laboratory (Table 3). The
content of these comments will vary on the basis of type of
supplemental testing option selected by the laboratory. These
comments are critical if screening-test–positive results are
reported as anti-HCV–positive on the basis of high s/co
ratios, because the health-care professional or other person
interpreting the results needs to understand the limitations of
the testing option used.
Before implementation, the laboratory staff should be edu-
cated regarding new methods of testing, calculating, and
reporting final results for the selected testing option. Labora-
tories also should inform and educate all customers regarding
the planned changes and what effects they will have on test
results generated. This information should be disseminated as
widely as possible (e.g., by laboratory bulletins, letters, Internet,
or continuing education programs).
Depending on the setting, reimbursement of clinical labo-
ratory tests used for reflex supplemental testing might depend
on documentation that the physician ordered the tests. This
documentation can be achieved through a printed requisition
form that clearly identifies for anti-HCV the specified level of
results of the screening test that will trigger additional supple-
mental testing and what type(s) of supplemental testing will
be performed. In addition, each of the supplemental tests (e.g.,
RIBA or NAT) that are offered by the laboratory should be
listed separately, because physicians should be able to order
these as they deem necessary for further medical evaluation.
Future Considerations
As new anti-HCV screening assays are approved or licensed
for use, each will need to be evaluated for its specificity among
populations with different anti-HCV prevalences. In addition,
before using a new assay to perform reflex supplemental test-
ing based on screening-test–positive s/co ratios, the s/co ratio
value at or above which supplemental test results are positive
>95% of the time in populations in which the test will be
used, should be determined. Such documentation also should
be required for approved screening assays if any modifications
are made to the testing procedures that might affect the s/co
ratio values. Similarly, the relation between screening-test–
positive results and the results of newly available supplemen-
tal tests will need to be evaluated.
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Terms and Abbreviations Used in This Report
ALT Alanine aminotransferase
Anti-HCV Antibody to hepatitis C virus
CIA Chemiluminescence immunoassay, a screening test format for anti-HCV (e.g., VITROS®
Anti-HCV assay)
EIA Enzyme immunoassay, a screening test format for anti-HCV (e.g., Abbott HCV EIA 2.0 and
ORTHO® HCV Version 3.0 ELISA)
FDA Food and Drug Administration
FDA-approved Assays intended only for in vitro diagnostic use; approved by the Center for Devices and Radiological
Health, FDA
FDA-licensed Assays intended primarily for donor screening; licensed by the Center for Biologics Evaluation and
Research, FDA
HCV Hepatitis C virus
HCV RNA Hepatitis C virus ribonucleic acid
NAT Nucleic acid test, detects HCV RNA by amplification of viral genetic sequences
OD Optical density
Reflex testing Additional testing automatically performed in response to a screening-test–positive result
RIBA® Recombinant immunoblot assay, a more specific serological anti-HCV assay
RT-PCR Reverse transcriptase-polymerase chain reaction amplification, a nucleic acid testing method for
detection of HCV RNA
S/Co ratio Signal to cut-off ratio, calculated by dividing the OD value of the sample being tested by the OD
value of the assay cut-off for that run
Screening tests Serologic immunoassays for detection of anti-HCV (e.g., Abbott HCV EIA 2.0, ORTHO HCV
Version 3.0 ELISA, and VITROS Anti-HCV)
Screening-test–negative Screening immunoassay test result interpreted as negative on the basis of criteria provided by the
manufacturer
Screening-test–positive Screening immunoassay test result interpreted as positive on the basis of criteria provided by the
manufacturer
STD Sexually transmitted disease
Supplemental test More specific test (e.g., RIBA or NAT) used to verify a positive anti-HCV screening test result
TMA Transcription-mediated amplification, a nucleic acid testing method for detection of HCV RNA
VA Veterans Affairs
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answer all of the questions. Questions with more than one correct answer
will instruct you to “Indicate all that apply.”
6. Submit your answers no later than February 7, 2006.
7. Immediately print your Certificate of Completion for your records.
By Mail or Fax
1. Read this MMWR (Vol. 52, RR-3), which contains the correct answers to
the questions beginning on the next page.
2. Complete all registration information on the response form, including your
name, mailing address, phone number, and e-mail address, if available.
3. Indicate whether you are registering for CME, CEU, or CNE credit.
4. Select your answers to the questions, and mark the corresponding letters on
the response form. To receive continuing education credit, you must
answer all of the questions. Questions with more than one correct answer
will instruct you to “Indicate all that apply.”
5. Sign and date the response form or a photocopy of the form and send no
later than February 7, 2006, to
Fax: 404-639-4198  Mail: MMWR CE Credit
Office of Scientific and Health Communications
Epidemiology Program Office, MS C-08
Centers for Disease Control and Prevention
1600 Clifton Rd, N.E.
Atlanta, GA 30333
6. Your Certificate of Completion will be mailed to you within 30 days.
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1. Why should laboratories verify anti-HCV screening-test–positive
results with a more specific supplemental assay before reporting the
results? (Indicate all that apply.)
A. To minimize unnecessary medical visits and psychological harm for
persons who test falsely positive.
B. To ensure that counseling, medical referral, and evaluation are targeted
to persons serologically confirmed as having been infected with HCV.
C. Because the accuracy of a screening-test–positive result for any given
specimen cannot be determined without clinical or risk information
regarding the person being tested.
D. Because the ordering physician might not understand the
interpretation of anti-HCV screening test results, when more specific
testing should be performed, and which tests should be considered for
this purpose.
2. Which of the following verifies a false-positive anti-HCV screening test
result? (Indicate all that apply.)
A. Screening-test–positive, recombinant immunoblot assay (RIBA®)-
negative.
B. Screening-test–positive, RIBA-indeterminate.
C. Screening-test–positive, nucleic acid test (NAT)-negative.
D. Screening-test–positive, NAT-negative, RIBA-negative.
3. Which of the following verifies a true positive anti-HCV screening test
result? (Indicate all that apply.)
A. Screening-test–positive, RIBA-positive.
B. Screening-test–positive, RIBA-indeterminate.
C. Screening-test–positive, NAT-positive.
D. Screening-test–positive, NAT-negative, RIBA-positive.
4. Which of the following is true regarding a RIBA indeterminate anti-
HCV test result? (Indicate all that apply.)
A. Might indicate recent infection in persons who are in the process of
seroconversion.
B. Might indicate a false-positive anti-HCV screening test result.
C. Occasionally is observed in persons with chronic HCV infection.
D. Further testing needs to be done.
5. Which of the following actions should be taken for specimens that are
anti-HCV screening-test–positive and NAT-negative. (Choose the one
correct answer.)
A. No further testing is required.
B. NAT should be repeated.
C. The screening immunoassay should be repeated.
D. RIBA should be performed.
6. Which of these statements concerning NAT for HCV RNA is not true?
(Choose the one correct answer.)
A. NAT can be used as a reflex supplemental assay to verify the presence
of anti-HCV.
B. NAT can detect the presence of active HCV infection.
C. In persons with a positive anti-HCV screening test, a single negative
NAT result indicates that the person is not infected with HCV.
D. In persons with a positive anti-HCV screening test, a single negative
NAT result cannot determine the HCV antibody or infection status.
Goal and Objectives
This MMWR provides guidelines for laboratory testing and result reporting of antibody to hepatitis C virus (anti-HCV). These guidelines were prepared by CDC
staff after consultation with staff members from other federal agencies and specialists in the field and are intended for laboratorians and other health-care professionals
who request, interpret, or perform anti-HCV tests. The goal of this report is to improve the accuracy and utility of reported anti-HCV test results for counseling and
medical evaluation of patients by health-care professionals and for surveillance by public health departments. Upon completion of this educational activity, the reader
should be able to describe 1) the importance of reflex supplemental testing to verify the presence of anti-HCV; 2) anti-HCV screening and supplemental test results;
and 3) when more specific anti-HCV testing should be performed and which tests should be used for this purpose.
To receive continuing education credit, please answer all of the following questions.
7. In which situations might HCV RNA be negative in persons with
active HCV infection? (Indicate all that apply.)
A. During the period of anti-HCV seroconversion in persons with acute
HCV infection.
B. During chronic HCV infection, if HCV RNA is intermittently positive.
C. None; persons with active HCV infection always test HCV RNA-positive.
D. Laboratory testing error resulting in a false-negative HCV RNA result.
8. Which of the following statements is true regarding procedures for
performing NAT for HCV RNA? (Indicate all that apply.)
A. Laboratories performing the test must have facilities specifically
designed for this purpose.
B. Whole blood can be stored at 2ºC–5ºC for <72 hours before separation
of serum or plasma.
C. Serum or plasma must be separated from cellular components within
2–6 hours after collection.
D. For storage >72 hours, serum or plasma should be frozen.
9. Which of the following are included in the recommendations for
laboratory testing and result reporting for anti-HCV? (Indicate all that
apply.)
A. Perform initial screening with an FDA-licensed or approved anti-
HCV test and report the final results on the basis of the screening test.
B. Only screening-test–negative samples can be reported as anti-HCV–
negative without further testing.
C. Reflex supplemental testing can be performed on the basis of
screening-test–positive signal-to-cut–off (s/co) ratios or on all
specimens with screening-test–positive results.
D. For screening-test–positive samples that require reflex supplemental
testing, the anti-HCV result should not be reported until the results
from the additional tests are available.
10. Which of the following statements is true regarding reflex
supplemental testing based on screening-test–positive s/co ratios?
(Indicate all that apply.)
A. Laboratories should use only screening tests for which high s/co ratios
have been demonstrated to predict a supplemental test-positive >95%
of the time among all populations tested.
B. Screening-test–positive samples with high s/co ratios can be reported
as anti-HCV–positive without supplemental testing, along with a
comment explaining the results.
C. Screening-test–positive samples with low s/co ratios require reflex
supplemental testing.
D. Screening-test–positive samples with low s/co ratios that test RIBA-
negative can be reported as anti-HCV–negative.
E. Screening-test–positive samples with low s/co ratios that are NAT-
negative require additional testing by RIBA to determine anti-HCV status.
11. For the currently approved screening immunoassays, what are the s/co
ratio values below which all screening-test–positive samples require
supplemental testing. (Choose the one correct answer.)
A. <3.8 for the enzyme immunoassays (EIA) and the chemiluminescence
assay (CIA).
B. <3.8 for the EIA and <8.0 for the CIA.
C. <4.0 for the EIA and <12.0 for the CIA.
D. None of the above.
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12. Indicate your work setting.
A. State/local health department.
B. Other public health setting.
C. Hospital clinic/private practice.
D. Managed care organization.
E. Academic institution.
F. Other.
13. Which best describes your professional activities?
A. Patient care — emergency/urgent care department.
B. Patient care — inpatient.
C. Patient care — primary-care clinic or office.
D. Laboratory/pharmacy.
E. Public health.
F. Other.
14. I plan to use these recommendations as the basis for . . . (Indicate all
that apply.)
A. health education materials.
B. insurance reimbursement policies.
C. local practice guidelines.
D. public policy.
E. other.
15. Each month, approximately how many patients do you test for
hepatitis C?
A. None.
B. 1–10.
C. 11–100.
D. 101–1,000.
E. >1,000.
16. How much time did you spend reading this report and completing the
exam?
A. <1.0 hour.
B. >1.0 hour but <2.0 hours.
C. >2.0 but <3.0 hours.
D. >3.0 hours.
17. After reading this report, I am confident I can describe the importance
of reflex supplemental testing to verify the presence of anti-HCV.
A. Strongly agree.
B. Agree.
C. Neither agree nor disagree.
D. Disagree.
E. Strongly disagree.
18. After reading this report, I am confident I can describe anti-HCV
screening and supplemental test results.
A. Strongly agree.
B. Agree.
C. Neither agree nor disagree.
D. Disagree.
E. Strongly disagree.
19. After reading this report, I am confident I can describe when more
specific anti-HCV testing should be performed and which tests should
be used for this purpose.
A. Strongly agree.
B. Agree.
C. Neither agree nor disagree.
D. Disagree.
E. Strongly disagree.
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20. The objectives are relevant to the goal of this report.
A. Strongly agree.
B. Agree.
C. Neither agree nor disagree.
D. Disagree.
E. Strongly disagree.
21. The box, tables, and figures are useful.
A. Strongly agree.
B. Agree.
C. Neither agree nor disagree.
D. Disagree.
E. Strongly disagree.
22. Overall, the presentation of the report enhanced my ability to
understand the material.
A. Strongly agree.
B. Agree.
C. Neither agree nor disagree.
D. Disagree.
E. Strongly disagree.
23. These recommendations will affect my practice.
A. Strongly agree.
B. Agree.
C. Neither agree nor disagree.
D. Disagree.
E. Strongly disagree.
24. The availability of continuing education credit influenced my decision
to read this report.
A. Strongly agree.
B. Agree.
C. Neither agree nor disagree.
D. Disagree.
E. Strongly disagree.
25. How did you learn about this continuing education activity?
A. Internet.
B. Advertisement (e.g., fact sheet, MMWR cover, newsletter, or journal).
C. Coworker/supervisor.
D. Conference presentation.
E. MMWR subscription.
F. Other.
Correct answers for questions 1–11.
1. A, B, C, and D; 2. A and D; 3. A, C, and D; 4. A, B, C, and D; 5. D; 6. C;
7. A, B, and D; 8. A, C, and D; 9. B, C, and D; 10. A, B, C, D, and E; 11. B.
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